Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical)

重组人源化抗CD19/CD3双特异性抗体（新时代药业）

Report date: 2026/03/19 17:18:40

Base Information

Drug NameRecombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical)

Drug Alias NameLNF-1904

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD19Anti-CD3

TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesShandong New Time Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShandong New Time Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A